	US 12,144,813 B2
	PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
Maya Ridinger, San Diego, CA (US); and Mark Erlander, San Diego, CA (US)
Assigned to Cardiff Oncology, Inc., San Diego, CA (US)
Filed by CARDIFF ONCOLOGY, INC., San Diego, CA (US)
Filed on Jun. 21, 2024, as Appl. No. 18/750,971.
Application 18/750,971 is a continuation of application No. 18/723,202, previously published as PCT/US2023/073865, filed on Sep. 11, 2023.
Claims priority of provisional application 63/515,831, filed on Jul. 26, 2023.
Claims priority of provisional application 63/405,466, filed on Sep. 11, 2022.
Prior Publication US 2024/0350498 A1, Oct. 24, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 35/04 (2006.01); A61P 35/04 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 39/3955 (2013.01); A61P 35/04 (2018.01)]

16 Claims

1. A method of treating a KRAS-mutated metastatic colorectal cancer, comprising:

(i) selecting a patient having a KRAS-mutated metastatic colorectal cancer who has not received any prior treatment for the metastatic colorectal cancer and has not received any prior treatment with bevacizumab; and

(ii) administering to the metastatic colorectal cancer patient an effective amount of onvansertib and bevacizumab in combination with a chemotherapy containing fluorouracil,

wherein onvansertib is administered multiple doses and bevacizumab is administered multiple doses during a treatment cycle.